Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

The goal of this clinical trial is to evaluate the efficacy and safety of radiotherapy combined with chemotherapy and anti-PD-1 immunotherapy followed by surgery for the primary and metastatic lesions in patients with limited metastatic gastric or gastroesophageal junction adenocarcinoma. The main questions it aims to answer are: 1) If the multimodal treatment which includes anti-PD-1 immunotherapy and local therapies will improve the survival of this group of patients. 2) If the multimodal treatment which includes anti-PD-1 immunotherapy and local therapies can be performed safely in this gro

Trial Details

NCT ID
NCT06121700
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • Radiotherapy targeted to the primary lesion
  • Radiotherapy targeted to the metastatic lesions
  • Anti-PD-1 monoclonal antibody
  • Trastuzumab
  • Chemotherapy
  • R0 total/subtotal gastrectomy with D2 lymphadenectomy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Histopathologically confirmed adenocarcinoma of stomach (G) or gastroesophageal junction (GEJ) (excluding Siewert type I).
  • Limited metastatic status of disease.
  • At least one evaluable lesion in CT/MRI according to RESIST 1.1 is required.
  • The status of HER2 is clear.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →